At the time of writing, Tarsus Pharmaceuticals Inc [TARS] stock is trading at $41.64, up 1.19%. An important factor to consider is whether the stock is rising or falling in short-term value. The TARS shares have gain 4.10% over the last week, with a monthly amount glided 4.91%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
On November 20, 2023, Goldman initiated with a Neutral rating and assigned a price target of $19 on the stock. William Blair started tracking the stock assigning a Outperform rating and suggested a price target of $44 on July 18, 2023. Guggenheim initiated its recommendation with a Buy. Barclays started tracking with a Overweight rating for this stock on August 01, 2022, and assigned it a price target of $40. In a note dated December 21, 2021, H.C. Wainwright initiated an Buy rating and provided a target price of $40 on this stock.
For the past year, the stock price of Tarsus Pharmaceuticals Inc fluctuated between $21.44 and $57.28. Currently, Wall Street analysts expect the stock to reach $71 within the next 12 months. Tarsus Pharmaceuticals Inc [NASDAQ: TARS] shares were valued at $41.64 at the most recent close of the market. An investor can expect a potential return of 70.51% based on the average TARS price forecast.
Analyzing the TARS fundamentals
According to Tarsus Pharmaceuticals Inc [NASDAQ:TARS], the company’s sales were 233.67M for trailing twelve months, which represents an 183.68% jump. Gross Profit Margin for this corporation currently stands at 0.93% with Operating Profit Margin at -0.47%, Pretax Profit Margin comes in at -0.45%, and Net Profit Margin reading is -0.45%. To continue investigating profitability, this company’s Return on Assets is posted at -0.21, Equity is -0.4 and Total Capital is -0.26.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Tarsus Pharmaceuticals Inc [NASDAQ:TARS] has a current ratio of 5.57. On the other hand, the Quick Ratio is 5.54, and the Cash Ratio is 2.04. Considering the valuation of this stock, the price to sales ratio is 7.49, the price to book ratio is 5.11.
Transactions by insiders
Recent insider trading involved Farrow Jeffrey S, that happened on Jun 17 ’25 when 13608.0 shares were sold. Officer, Farrow Jeffrey S completed a deal on Jun 17 ’25 to buy 13608.0 shares. Meanwhile, Chief Medical Officer Lin Elizabeth Yeu sold 1006.0 shares on Jun 16 ’25.
